Efficacy of therapy with bortezomib in solid tumors: A review based on 32 clinical trials

Future Oncology

Volumn 10, Issue 10, 2014, Pages 1795-1807

  Huang, Zebo ^a   Wu, Yinxia ^b   Zhou, Xin ^a   Xu, Jun ^a   Zhu, Wei ^a   Shu, Yongqian ^a   Liu, Ping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b YANGZHOU UNIVERSITY   (China)

Author keywords

bortezomib; clinical trials; solid tumors; ubiquitin proteasome system

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; PROTEASOME; UBIQUITIN; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE REGULATION; CLINICAL TRIAL (TOPIC); DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; MONOTHERAPY; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PROTEIN DEGRADATION; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; META ANALYSIS; MORTALITY; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; NEOPLASMS; PYRAZINES; TREATMENT OUTCOME;

EID: 84907940387     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.30     Document Type: Review

References (68)

1. Moreau P, Richardson PG, Cavo M et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120, 947-959 (2012).
2. Ciechanover A. Intracellular protein degradation: From a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture). Angew. Chem. Int. Ed. Engl. 44, 5944-5967 (2005).
3. Moore BS, Eustaquio AS, McGlinchey RP. Advances in and applications of proteasome inhibitors. Curr. Opin. Chem. Biol. 12, 434-440 (2008).
4. Chen W, Lee J, Cho SY, Fine HA. Proteasome-mediated destruction of the cyClin. a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res. 64, 3949-3957 (2004).
5. Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 50, 57-74 (1999).
6. Blagosklonny MV. P53: An ubiquitous target of anticancer drugs. Int. J Cancer. 98, 161-166 (2002).
7. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc. Natl Acad. Sci. USA 97, 3850-3855 (2000).
8. Pagano M, Tam SW, Theodoras AM et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-685 (1995).
9. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7, 758-765 (2005).
10. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59(11), 2615-2622 (1999).
11. ClinicalTrials.gov. www.clinicaltrials.gov
12. Kondagunta GV, Drucker B, Schwartz L et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 22, 3720-3725 (2004).
13. Alberts SR, Foster NR, Morton RF et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) randomized Phase II study. Ann. Oncol. 16, 1654-1661 (2005).
14. Fanucchi MP, Fossella FV, Belt R et al. Randomized Phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 5025-5033 (2006).
15. Kozuch PS, Rocha-Lima CM, Dragovich T et al. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: Results from a randomized Phase II study. J. Clin. Oncol. 26, 2320-2326 (2008).
16. Lilenbaum R, Wang X, Gu L, Kirshner J, Lerro K, Vokes E. Randomized Phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J. Clin. Oncol. 27, 4487-4491 (2009).
17. Lynch TJ, Fenton D, Hirsh V et al. A randomized Phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J. Thorac. Oncol. 4, 1002-1009 (2009).
18. Lara PJ, Longmate J, Reckamp K et al. Randomized Phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: A California Cancer Consortium trial. Clin. Lung Cancer. 12, 33-37 (2011).
19. Scagliotti GV, Germonpre P, Bosquee L et al. A randomized Phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 68, 420-426 (2010).
20. Li T, Ho L, Piperdi B et al. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 68, 89-93 (2010).
21. Ramalingam SS, Davies AM, Longmate J et al. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: A California Cancer Consortium Phase II study (NCI 7003). J. Thorac. Oncol. 6, 1741-1745 (2011).
22. Besse B, Planchard D, Veillard AS et al. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer 76, 78-83 (2012).
23. Davies AM, Chansky K, Lara PJ et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: A Phase II Southwest Oncology Group Study (S0339). J. Thorac. Oncol. 4, 87-92 (2009).
24. Markovic SN, Geyer SM, Dawkins F et al. A Phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103, 2584-2589 (2005).
25. Croghan GA, Suman VJ, Maples WJ et al. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: A Phase 2 consortium study. Cancer 116, 3463-3468 (2010).
26. Mackay H, Hedley D, Major P et al. A Phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin. Cancer Res. 11, 5526-5533 (2005).
27. Shah MA, Power DG, Kindler HL et al. A multicenter, Phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest. New Drugs 29, 1475-1481 (2011).
28. Jatoi A, Dakhil SR, Foster NR et al. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: Phase II results from the North Central Cancer Treatment Group (N044B). J. Thorac. Oncol. 3, 516-520 (2008).
29. Hainsworth JD, Meluch AA, Spigel DR et al. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: A Minnie Pearl Cancer Research Network Phase II trial. Clin. Genitourin. Cancer. 5, 278-283 (2007).
30. Yang CH, Gonzalez-Angulo AM, Reuben JM et al. Bortezomib (VELCADE) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits. Ann. Oncol. 17, 813-817 (2006).
31. Trinh XB, Sas L, Van Laere SJ et al. A Phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncol. Rep. 27, 657-663 (2012).
32. Putzer D, Gabriel M, Kroiss A et al. First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib. Clin. Nucl. Med. 37, 539-544 (2012).
33. Maki RG, Kraft AS, Scheu K et al. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 103, 1431-1438 (2005).
34. Gomez-Abuin G, Winquist E, Stadler WM et al. A Phase II study of PS-341 (bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago Phase II consortia. Invest New Drugs. 25, 181-185 (2007).
35. Rosenberg JE, Halabi S, Sanford BL et al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann. Oncol. 19, 946-950 (2008).
36. Shah MH, Young D, Kindler HL et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 10, 6111-6118 (2004).
37. Fennell DA, McDowell C, Busacca S et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J. Thorac. Oncol. 7, 1466-1470 (2012).
38. Kim GP, Mahoney MR, Szydlo D et al. An international, multicenter Phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs 30, 387-394 (2012).
39. Chung CH, Aulino J, Muldowney NJ et al. Nuclear factor-kappa B pathway and response in a Phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 21, 864-870 (2010).
40. Friday BB, Anderson SK, Buckner J et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: Anorth central cancer treatment group study. Neuro. Oncol. 14, 215-221 (2012).
41. Wang H, Cao Q, Dudek AZ. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 32, 1027-1031 (2012).
42. Parma G, Mancari R, Del CG et al. An open-label Phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. Int. J Gynecol. Cancer, 22, 792-800 (2012).
43. Irvin WJ, Orlowski RZ, Chiu WK et al. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin. Breast Cancer 10, 465-470 (2010).
44. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 458, 438-444 (2009).
45. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discov. 10, 29-46 (2011).
46. Adams J. Proteasome inhibition: A novel approach to cancer therapy. Trends Mol. Med. 8, S49-S54 (2002).
47. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 5, 18 (2005).
48. Dou QP, Li B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist. Updat. 2, 215-223 (1999).
49. Adams J. The proteasome: A suitable antineoplastic target. Nat. Rev. Cancer. 4, 349-360 (2004).
50. Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427 (2002).
51. Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Eng. J. Med. 348, 2609-2617 (2003).
52. Richardson PG, Barlogie B, Berenson J et al. Extended follow-up of a Phase II trial in relapsed, refractory multiple myeloma: Final time-To-event results from the SUMMIT trial. Cancer 106, 1316-1319 (2006).
53. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Eng. J. Med. 352, 2487-2498 (2005).
54. Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a Phase 3 trial in relapsed multiple myeloma: Final time-To-event results of the APEX trial. Blood 110(10), 3557-3560 (2007).
55. Aghajanian C, Soignet S, Dizon DS et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8, 2505-2511 (2002).
56. Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 21, 524-528 (2007).
57. Canfield SE, Zhu K, Williams SA, McConkey DJ. Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol. Cancer Ther. 5, 2043-2050 (2006).
58. Buac D, Shen M, Schmitt S et al. From Bortezomib to other Inhibitors of the proteasome and beyond. Curr. Pharm. Des. 19, 4025-4038 (2013).
59. Sloss CM, Wang F, Liu R et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 14, 5116-5123 (2008).
60. Ayala G, Yan J, Li R et al. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin. Cancer Res. 14, 7511-7518 (2008).
61. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J. Natl Cancer Inst. 103, 1007-1017 (2011).
62. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: Pivotal roles of Snail repression and RKIP induction. Oncogene 28, 3573-3585 (2009).
63. Kupperman E, Lee EC, Cao Y et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70, 1970-1980 (2010).
64. Piva R, Ruggeri B, Williams M et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111, 2765-2775 (2008).
65. Chauhan D, Singh AV, Aujay M et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116, 4906-4915 (2010).
66. Dick LR, Fleming PE. Building on bortezomib: Second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 15, 243-249 (2010).
67. Esseltine DL, Mulligan G. An historic perspective of proteasome inhibition. Semin. Hematol. 49, 196-206 (2012).
68. Yang H, Zonder JA, Dou QP. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin. Investig. Drugs. 18, 957-971 (2009).